The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma.
暂无分享,去创建一个
Francis Impens | Kris Gevaert | Frank Speleman | Pieter Mestdagh | Jo Vandesompele | Bart Ghesquière | Alexander Schramm | F. Speleman | J. Vandesompele | E. Fredlund | K. Gevaert | P. Mestdagh | J. Schulte | H. Axelson | F. Impens | B. Ghesquière | M. Zollo | A. Schramm | A. Thomas-Tikhonenko | Pasqualino de Antonellis | M. Dews | Gert Van Peer | Johannes H Schulte | Håkan Axelson | Kristoffer von Stedingk | Anna-Karin Boström | Erik Fredlund | Gert Van Peer | Pasqualino De Antonellis | Kristoffer von Stedingk | Stefanie Schulte | Michael Dews | Andrei Thomas-Tikhonenko | Massimo Zollo | Anna-Karin Boström | S. Schulte | Francis Impens
[1] N. Rajewsky,et al. Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.
[2] Niklaas Colaert,et al. In Vitro and in Vivo Protein-bound Tyrosine Nitration Characterized by Diagonal Chromatography* , 2009, Molecular & Cellular Proteomics.
[3] E. Furth,et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster , 2006, Nature Genetics.
[4] M. Mann,et al. Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.
[5] G. Mincione,et al. Transforming growth factor beta regulates differentiation and proliferation of human neuroblastoma. , 1996, Experimental cell research.
[6] Steven P Gygi,et al. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.
[7] L. Lim,et al. A microRNA component of the p53 tumour suppressor network , 2007, Nature.
[8] B. Olson,et al. Inhibition of Transforming Growth Factor (TGF)- 1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF- Type I Receptor Kinase Activity: SB-431542 , 2002 .
[9] S. Lowe,et al. miR-19 is a key oncogenic component of mir-17-92. , 2009, Genes & development.
[10] G. Semenza,et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. , 2007, Cancer cell.
[11] F. Slack,et al. Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.
[12] Jo Vandesompele,et al. RTPrimerDB: the portal for real-time PCR primers and probes , 2008, Nucleic Acids Res..
[13] C. Leonetti,et al. Increased TGFβ Type II Receptor Expression Suppresses the Malignant Phenotype and Induces Differentiation of Human Neuroblastoma Cells , 2000 .
[14] Roger R. Gomis,et al. TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.
[15] John M. Maris,et al. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma , 2008, Proceedings of the National Academy of Sciences.
[16] M. Schwab,et al. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. , 1990, Cancer research.
[17] Patrick Warnat,et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Denis Vivien,et al. Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene , 1998, The EMBO journal.
[19] Pieter Mestdagh,et al. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA , 2008, Nucleic acids research.
[20] F. Verrecchia,et al. Identification of Novel TGF-β/Smad Gene Targets in Dermal Fibroblasts using a Combined cDNA Microarray/Promoter Transactivation Approach* , 2001, The Journal of Biological Chemistry.
[21] J. Lovén,et al. MYCN-regulated microRNAs repress estrogen receptor-α (ESR1) expression and neuronal differentiation in human neuroblastoma , 2010, Proceedings of the National Academy of Sciences.
[22] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[23] S Rozen,et al. Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.
[24] M. Sporn,et al. Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines. , 1995, Cancer research.
[25] Kathryn A. O’Donnell,et al. c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.
[26] Chris F. Taylor,et al. RDML: structured language and reporting guidelines for real-time quantitative PCR data , 2009, Nucleic acids research.
[27] S. Lowe,et al. A microRNA polycistron as a potential human oncogene , 2005, Nature.
[28] S. Grimmond,et al. The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition , 2008, Genome Biology.
[29] D. Iliopoulos,et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. , 2008, Cancer cell.
[30] G. Hannon,et al. The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response , 2009, Proceedings of the National Academy of Sciences.
[31] L. Lim,et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. , 2007, Molecular cell.
[32] Y. Yatabe,et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. , 2005, Cancer research.
[33] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[34] Lennart Martens,et al. Chromatographic Isolation of Methionine-containing Peptides for Gel-free Proteome Analysis , 2002, Molecular & Cellular Proteomics.
[35] D. Bartel,et al. The impact of microRNAs on protein output , 2008, Nature.
[36] F. Westermann,et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors , 2010, Oncogene.
[37] A. Donfrancesco,et al. Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma through p21 and BIM , 2008, PloS one.
[38] Jing Wang,et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes , 2008, Nature Immunology.
[39] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[40] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[41] Moshe Oren,et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. , 2007, Molecular cell.
[42] George A Calin,et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer , 2007, Molecular Cancer.
[43] G. Mortier,et al. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data , 2007, Genome Biology.
[44] Frank Speleman,et al. A novel and universal method for microRNA RT-qPCR data normalization , 2009, Genome Biology.
[45] C. Croce,et al. A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[46] Francis Impens,et al. Rover: A tool to visualize and validate quantitative proteomics data from different sources , 2010, Proteomics.
[47] C. Burge,et al. Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.
[48] E. Furth,et al. The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. , 2010, Cancer research.
[49] D. N. Perkins,et al. Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.